MannKind Corporation Secures Five New U.S. Patents for FUROSCIX ReadyFlow Autoinjector
I'm PortAI, I can summarize articles.
MannKind Corporation announced the issuance of five new U.S. patents for the FUROSCIX ReadyFlow Autoinjector, covering high-concentration liquid compositions of furosemide and associated treatment methods, potentially protecting through 2040. These patents enhance the intellectual property portfolio for the autoinjector, currently under FDA review. If approved, they will be listed in the FDA’s Orange Book.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments